Intravaginal DHEA (Prasterone/Intrarosa)
Intravaginal DHEA (Prasterone/Intrarosa) offers a promising approach for women experiencing moderate-to-severe dyspareunia related to genitourinary syndrome of menopause (GSM). This FDA-approved vaginal insert delivers dehydroepiandrosterone (DHEA) directly to vaginal tissues, where it supports local hormone production without significantly affecting systemic hormone levels. Understanding this treatment can be especially relevant for postmenopausal women seeking relief from vaginal dryness, discomfort during intercourse, and other symptoms linked to vaginal atrophy.
How It Works
Intravaginal DHEA works through a unique intracrine mechanism. Instead of simply supplying estrogen or testosterone, DHEA acts as a precursor hormone that vaginal cells convert internally into both estrogen and androgen hormones. These cells contain enzymes capable of transforming DHEA into estradiol (a form of estrogen) and testosterone or dihydrotestosterone (DHT), the primary androgen.
This local hormone production supports the vaginal tissue in several ways:
- Epithelial restoration: Estrogen and androgen stimulate the thickening and maturation of the vaginal lining, which tends to thin after menopause.
- Moisture and elasticity: Hormonal effects improve blood flow and encourage moisture retention, reducing dryness and increasing tissue flexibility.
- pH normalization: Balanced hormone levels help restore a healthy vaginal pH, supporting the natural microbiome and lowering infection risk.
Importantly, because the conversion happens within the vaginal cells, systemic hormone levels remain largely unchanged, staying within postmenopausal ranges. This means the treatment may provide targeted relief without the broader hormonal exposure seen with some systemic or even vaginal estrogen therapies.
What the Evidence Says
Clinical studies of intravaginal DHEA have demonstrated improvements in symptoms of GSM, particularly moderate-to-severe dyspareunia (pain during intercourse) and vaginal dryness. Women using the 6.5 mg daily vaginal insert reported:
- Decreased pain during sexual activity
- Increased vaginal moisture and lubrication
- Restoration of vaginal epithelial thickness and health
- Normalization of vaginal pH to premenopausal levels
Because this treatment is FDA-approved, it has passed rigorous safety and efficacy assessments. Moreover, research suggests that intravaginal DHEA does not raise systemic estrogen or androgen levels, making it a potentially safer option for women who cannot or prefer not to use traditional vaginal estrogen.
That said, limitations remain. Most studies focus on postmenopausal women with moderate-to-severe symptoms, so its benefits for milder symptoms or other populations are less clear. Additionally, long-term safety data beyond one year are limited, and individual responses can vary. As with all hormone-related therapies, ongoing research continues to refine our understanding of risks and benefits.
Clinical Context
Intravaginal DHEA is typically prescribed for postmenopausal women experiencing symptoms related to genitourinary syndrome of menopause, including vaginal dryness, atrophy, and painful intercourse. It is particularly considered when:
- Vaginal estrogen is contraindicated or not preferred
- Symptoms significantly impact quality of life
- Other non-hormonal lubricants and moisturizers have provided insufficient relief
Treatment involves daily insertion of the 6.5 mg prasterone vaginal insert, usually under the guidance of a qualified healthcare provider or physician. Regular monitoring may include symptom assessment and, if appropriate, hormone level checks to ensure systemic hormones remain stable.
While well-tolerated by most women, any new or worsening symptoms should be discussed promptly with a healthcare provider. Intravaginal DHEA is one tool among several in managing GSM, and personalized care is essential to optimize outcomes.
Key Takeaways
- Intravaginal DHEA (Prasterone/Intrarosa) provides local hormone support by converting into estrogen and androgen within vaginal cells, improving symptoms of GSM.
- It offers dual hormonal benefits without significantly raising systemic hormone levels, which may be preferable for some postmenopausal women.
- Clinical studies show it can reduce dyspareunia and vaginal dryness while restoring vaginal tissue health and pH balance.
- Use should be supervised by a qualified healthcare provider, with ongoing symptom monitoring to ensure safety and effectiveness.
Frequently Asked Questions
Q: How is intravaginal DHEA different from vaginal estrogen therapy?
A: Intravaginal DHEA is converted locally within vaginal cells into both estrogen and androgens, whereas vaginal estrogen therapy involves direct delivery of estrogen. DHEA does not significantly increase systemic hormone levels, which may reduce certain risks associated with estrogen use.
Q: Who is a good candidate for intravaginal DHEA treatment?
A: Postmenopausal women experiencing moderate-to-severe vaginal dryness or pain during intercourse, especially those who cannot or prefer not to use vaginal estrogen, may benefit from this treatment. A physician-supervised evaluation is important to determine suitability.
Q: How long does it take to notice improvements with intravaginal DHEA?
A: Many women report symptom relief within a few weeks of daily use, though full benefits on vaginal tissue health may take several months. Consistent use as directed by a healthcare provider is key.